Mineralys Therapeutics (MLYS) Research & Development (2022 - 2026)

Mineralys Therapeutics has disclosed Research & Development across 5 years of filings, most recently posting $24.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $24.4 million, down 35.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $118.5 million (down 32.56% YoY), and the FY2025 annual result was $132.0 million, down 21.69% from the prior year.
• Research & Development came in at $24.4 million for Q1 2026 at Mineralys Therapeutics, roughly flat from $24.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $54.0 million in Q3 2024 to a low of $5.6 million in Q2 2022.
• The 5-year median for Research & Development is $24.4 million (2026), against an average of $24.8 million.
• Across the five-year window, Research & Development soared 271.33% in 2023 and plunged 45.25% in 2025, its largest moves.
• Mineralys Therapeutics' Research & Development stood at $7.8 million in 2022, then surged by 202.95% to $23.7 million in 2023, then surged by 88.17% to $44.6 million in 2024, then slumped by 45.25% to $24.4 million in 2025, then dropped by 0.15% to $24.4 million in 2026.
• The last three Research & Development figures came in at $24.4 million (Q1 2026), $24.4 million (Q4 2025), and $31.4 million (Q3 2025), per Business Quant data.